

# ASTRAZENECA PLC

## Non-Statutory Financial Statements

31 December 2006

Registered number 2723534



EDX \*ERRO300N\* 1285  
6/3/07  
COMPANIES HOUSE

A47 \*APAZTOOP\* 477  
20/03/2007  
COMPANIES HOUSE

A18 06/03/2007 373  
COMPANIES HOUSE

28.3.07 111


# ASTRAZENECA PLC

## PROFIT AND LOSS ACCOUNT for the year ended 31 December 2006

	Notes	31 December 2006 \$m	31 December 2005 \$m
Turnover		-	-
Operating costs		(9)	(8)
<b>Operating loss</b>		<b>(9)</b>	<b>(8)</b>
Income from shares in subsidiary undertakings		681	1,183
<b>Profit on ordinary activities before interest</b>		<b>672</b>	<b>1,175</b>
Net interest and exchange gains/(losses)	2	1	(20)
<b>Profit on ordinary activities before taxation</b>		<b>673</b>	<b>1,155</b>
Taxation		(21)	113
<b>Net profit for the year</b>		<b>652</b>	<b>1,268</b>
Dividends to Shareholders	3	(2,217)	(1,676)
<b>Loss retained for the year</b>		<b>(1,565)</b>	<b>(408)</b>

There are no gains or losses other than those reported above, therefore a statement of recognised gains and losses has not been presented

The Profit and Loss Account and accompanying notes were approved by the Board of Directors on 31 January 2007 and were signed on its behalf by



David R Brennan

Director



Jonathan Symonds

Director

ASTRAZENECA PLC

**BALANCE SHEET**


	Notes	31 December 2006 \$m	31 December 2005 \$m
<b>Fixed assets</b>			
Fixed asset investments	4	19,118	24,856
<b>Current assets</b>			
External debtors - other		9	27
Debtors – amounts owed by subsidiaries		1,382	340
		1,391	367
<b>Total assets</b>		20,509	25,223
<b>Creditors due within one year</b>			
Short-term borrowings		(7)	(5)
Other creditors		(12)	(5)
Amounts owed to subsidiaries		(14)	(10)
		(33)	(20)
<b>Net current assets</b>		1,358	347
<b>Total assets less current liabilities</b>		20,476	25,203
<b>Creditors due after more than one year</b>			
Loans		(1,030)	(1,030)
<b>Net assets</b>		19,446	24,173
<b>Capital and reserves</b>			
Called-up share capital	5	383	395
Share premium account	6	1,671	692
Capital redemption reserve	6	71	53
Other reserves	6	1,841	1,841
Profit and loss account	6	15,480	21,192
<b>Shareholders' funds - equity interests</b>	7	19,446	24,173

The Balance Sheet and accompanying notes were approved by the Board of Directors on 31 January 2007 and were signed on its behalf by



David R Brennan

Director



Jonathan Symonds

Director

# ASTRAZENECA PLC

## NOTES RELATING TO THE FINANCIAL STATEMENTS

### 1 Basis of presentation of financial information

These AstraZeneca PLC non-statutory financial statements are presented in accordance with the accounting policies set out in the 2005 annual accounts

These financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2005 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985

### 2 Net interest and exchange losses

	31 December 2006 \$m	31 December 2005 \$m
<b>Interest payable and similar charges</b>		
Payable to subsidiary undertakings	(20)	(20)
External interest payable	(41)	(41)
Net exchange losses	-	(20)
	(61)	(81)
<b>Interest receivable and similar income</b>		
Receivable from subsidiary undertakings	61	61
Net exchange gains	1	-
<b>Net interest and exchange gains/(losses)</b>	<b>1</b>	<b>(20)</b>

## NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

### 3 Dividends to shareholders

	31 Dec 2006 Per Share	31 Dec 2005 Per Share	31 Dec 2006 \$m	31 Dec 2005 \$m
2 <sup>nd</sup> interim/final	\$0 920	\$0 645	1,453	1,061
1 <sup>st</sup> interim	\$0 490	\$0 380	764	615
	\$1 410	\$1 025	2,217	1,676

### 4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost			
At beginning of period	6,715	18,141	24,856
Repayment of loan	-	(5,738)	(5,738)
At end of period	6,715	12,403	19,118

### 5 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	31 Dec 2006 \$m	31 Dec 2006 \$m	31 Dec 2005 \$m
Ordinary Shares (\$0 25 each)	383	383	395
Unissued Ordinary Shares (\$0 25 each)	217	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	383	395

The movements in share capital during the period can be summarised as follows

	No shares (millions)	\$m
At beginning of period	1,581	395
Issue of shares	23	6
Repurchase of shares	(72)	(18)
At end of period	1,532	383

## NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

### 6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 31 Dec 2006 \$m	Total 31 Dec 2005 \$m
At beginning of period	692	53	1,841	21,192	23,778	27,028
Net profit for the period	-	-	-	652	652	1,268
Dividends	-	-	-	(2,217)	(2,217)	(1,676)
Share repurchase	-	18	-	(4,147)	(4,129)	(2,984)
Share premiums	979	-	-	-	979	142
At end of period	1,671	71	1,841	15,480	19,071	23,778
Distributable reserves at end of period	-	-	1,712	4,351	6,063	5,058

At 31 December 2006 \$11,129m (31 December 2005 \$16,867m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the year \$5,738m of the profit was released by repayment. Subsequent to the period end a further \$1,965m was repaid on 26 January 2007, resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

### 7 Reconciliation of movements in shareholders' funds

	31 December 2006 \$m	31 December 2005 \$m
Net gains for the financial period	652	1,268
Dividends	(2,217)	(1,676)
	(1,565)	(408)
Issue of AstraZeneca Ordinary Shares	985	143
Repurchase of AstraZeneca Ordinary Shares	(4,147)	(3,001)
Net reduction in shareholders' funds	(4,727)	(3,266)
Shareholders' funds at beginning of period	24,173	27,439
Shareholders' funds at end of period	19,446	24,173